Table 1 General clinical and imaging data of all participants (n = 146).
From: Glymphatic dysfunction as a biomarker for post-stroke cognitive impairment
Characteristics | All participants, n = 1461 | Non-Stroke cohorts | Stroke cohort n = 511 | |
|---|---|---|---|---|
Healthy controls, n = 481 | n-VCI, n = 471 | |||
Female | 82 (56.2) | 35 (72.9) | 31 (66.0) | 16 (31.4) |
Age, years, | 63 (39–73) | 42 (36–58) | 71 (64–78) | 64 (51–73) |
Baseline MMSE | 25 (15–30) | 30 (27–30) | 20 (18–25) | 13 (0–26) |
Stroke risk factors | ||||
Previous stroke | 31 (21.2) | 0 (0.0) | 0 (0.0) | 31 (60.8) |
Hypertension | 45 (30.8) | 7 (14.6) | 5 (10.6) | 33 (64.7) |
DM | 24 (16.4) | 3 (6.2) | 5 (10.6) | 16 (31.4) |
AF | 6 (4.1) | 0 (0.0) | 0 (0.0) | 6 (11.8) |
Current smoking | 24 (16.4) | 3 (6.2) | 4 (8.5) | 17 (33.3) |
Current drinking | 18 (12.3) | 2 (4.2) | 3(6.4) | 13 (25.5) |
CSVD imaging markers | ||||
Degree of WMH | ||||
0 | 40 (27.4) | 28 (58.3) | 5 (10.6) | 7 (13.7) |
1 | 75 (51.4) | 20 (41.7) | 26 (55.3) | 29 (56.9) |
2 | 20 (13.7) | 0 (0.0) | 11 (23.4) | 9 (17.6) |
3 | 11 (7.5) | 0 (0.0) | 5 (10.6) | 6 (11.8) |
Degree of EPVS | ||||
0 | 59 (40.4) | 37 (77.1) | 13 (27.7) | 9 (17.6) |
1 | 53 (36.3) | 9 (18.8) | 18 (38.3) | 26 (51.0) |
2 | 23 (15.8) | 2 (4.2) | 9 (19.1) | 12 (23.5) |
3 | 7 (4.8) | 0 (0) | 3 (6.4) | 4 (7.8) |
4 | 4 (2.7) | 0 (0) | 4 (8.5) | 0 (0) |
GCA score | ||||
0 | 31 (21.2) | 25 (52.1) | 2 (4.3) | 4 (7.8) |
1 | 71 (48.6) | 18 (37.5) | 22 (46.8) | 31 (60.8) |
2 | 40 (27.4) | 5 (10.4) | 21 (44.7) | 14 (27.5) |
3 | 4 (2.7) | 0 (0.0) | 2 (4.3) | 2 (3.9) |
Lacune ≥ 1 | 43 (29.5) | 2 (4.2) | 7 (14.9) | 34 (66.7) |
